How many stocks are there of Imugene?
The current number of stocks of Imugene is 7.09 B undefined.
Imugene Stocks 2024
Imugene Stocks
7.09 B
Ticker
IMU.AX
ISIN
AU000000IMU9
WKN
891460
In 2024, Imugene had 7.09 B outstanding stocks, a 12.96% change from the 6.28 B stocks in the previous year.
The Imugene Stocks history
| YEAR | NUMBER OF STOCKS (undefined AUD) |
|---|---|
| 2030e | 7.09 |
| 2029e | 7.09 |
| 2028e | 7.09 |
| 2027e | 7.09 |
| 2026e | 7.09 |
| 2025e | 7.09 |
| 2024 | 7.09 |
| 2023 | 6.28 |
| 2022 | 5.64 |
| 2021 | 4.66 |
| 2020 | 4.07 |
| 2019 | 3.58 |
| 2018 | 2.64 |
| 2017 | 2.09 |
| 2016 | 1.33 |
| 2015 | 1.19 |
| 2014 | 0.7 |
| 2013 | 0.33 |
| 2012 | 0.14 |
| 2011 | 0.14 |
| 2010 | 0.14 |
| 2009 | 0.15 |
| 2008 | 0.14 |
| 2007 | 0.13 |
| 2006 | 0.13 |
| 2005 | 0.12 |
Imugene shares outstanding AU000000IMU9 · 891460
The number of shares was Imugene in 2023 — This indicates how many shares 6.276 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Imugene earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Imugene's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Imugene’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Imugene's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2005 | 121.2 M Aktien |
| 2006 | 131.76 M Aktien |
| 2007 | 131.76 M Aktien |
| 2008 | 137.67 M Aktien |
| 2009 | 152.36 M Aktien |
| 2010 | 144.94 M Aktien |
| 2011 | 144.94 M Aktien |
| 2012 | 144.94 M Aktien |
| 2013 | 328.82 M Aktien |
| 2014 | 695.44 M Aktien |
| 2015 | 1.19 B Aktien |
| 2016 | 1.33 B Aktien |
| 2017 | 2.09 B Aktien |
| 2018 | 2.64 B Aktien |
| 2019 | 3.58 B Aktien |
| 2020 | 4.07 B Aktien |
| 2021 | 4.66 B Aktien |
| 2022 | 5.64 B Aktien |
| 2023 | 6.28 B Aktien |
| 2024 | 7.09 B Aktien |
| 2025e | 7.09 B Aktien |
| 2026e | 7.09 B Aktien |
| 2027e | 7.09 B Aktien |
| 2028e | 7.09 B Aktien |
| 2029e | 7.09 B Aktien |
| 2030e | 7.09 B Aktien |
Imugene Aktienanalyse
What does Imugene do?
Imugene Ltd is an Australian biotechnology company focused on the development of immunotherapies for various diseases, including cancer and infectious diseases. The company was founded in 2014 and is headquartered in Sydney. Imugene's business model is based on collaboration with academic institutions and other biotechnology companies to identify and develop promising drug candidates. The company also works closely with clinical researchers and physicians to accelerate drug development and ensure they meet patient needs. Imugene specializes in four different areas: oncology, immunology, infectious diseases, and neuroscience. Each area focuses on the development of drugs for specific diseases and medical needs. In the field of oncology, Imugene is focused on developing immunotherapy products for the treatment of breast cancer, colon cancer, lung cancer, and other types of cancer. Immunotherapy aims to strengthen the body's immune system to better destroy cancer cells. In the field of immunology, Imugene is focused on developing immunotherapy products for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Immunotherapy aims to modulate the immune system to eliminate disease-causing cells. In the field of infectious diseases, Imugene is focused on developing vaccines and products for the treatment of diseases such as COVID-19, influenza, hepatitis B, and HPV. Vaccines aim to activate the immune system to recognize and destroy pathogens before they can cause harm in the body. In the field of neuroscience, Imugene is focused on developing drugs for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's. These drugs aim to stimulate the brain's neuroprotective mechanisms to reduce nerve damage. Imugene has several promising products in the pipeline that aim to demonstrate the efficacy and safety of immunotherapy and other therapies. The company has already conducted clinical trials for some of these products, while others are still in preclinical development. One of Imugene's key products is HER-Vaxx, a vaccine for the treatment of breast cancer that activates the body's immune system against the HER2 protein, which promotes cancer growth in some individuals. The vaccine has been tested in clinical trials and has shown promising results. Another promising product from Imugene is PD1-Vaxx, a vaccine for the treatment of lung cancer that targets the activation of an important immune cell sensor. Preliminary study results suggest that treatment with PD1-Vaxx is synergistic with checkpoint inhibitors, another type of cancer treatment medication. Imugene is also working on a range of products for the treatment of COVID-19, including IMM-013, a vaccine against SARS-CoV-2, and IMM-036, an antibody against the virus. These products are being tested in preclinical development and are aimed at helping to contain the spread of the pandemic. Overall, Imugene aims to develop innovative drugs for the treatment of various medical needs. The company relies on close collaboration with academic and clinical partners to accelerate drug development and ensure its products meet the highest standards of efficacy and safety. Imugene ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Imugene's Shares Outstanding
Imugene's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Imugene’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Imugene’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Imugene’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Imugene stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Imugene are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Imugene evolved in recent years?
The number of shares of Imugene has increased by 12.96% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Imugene as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Imugene?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Imugene pay?
Over the past 12 months, Imugene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Imugene is expected to pay a dividend of 0 AUD.
What is the dividend yield of Imugene?
The current dividend yield of Imugene is .
When does Imugene pay dividends?
Imugene pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Imugene?
Imugene paid dividends every year for the past 0 years.
What is the dividend of Imugene?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Imugene located?
Imugene is assigned to the 'Health' sector.
Wann musste ich die Aktien von Imugene kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Imugene from 9/28/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/28/2024.
When did Imugene pay the last dividend?
The last dividend was paid out on 9/28/2024.
What was the dividend of Imugene in the year 2023?
In the year 2023, Imugene distributed 0 AUD as dividends.
In which currency does Imugene pay out the dividend?
The dividends of Imugene are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Imugene
Our stock analysis for Imugene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Imugene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
